Among these inhibitors, only four drugs as potential therapeutics, including Donepezil (AChE inhibitor), Galantamine (AChE inhibitor), Rivastigmine (reverse inhibitor of both AChE and butyrylcholinesterase or BChE), and Memantine are currently available in the market for use in the AD patients (Table 1). Here, ACHE is linked to Alzheimer disease.